Search the Newsreel

ETFs Investing in Charles River Laboratories International, Inc. Stocks

This article lists various ETFs that include Charles River Laboratories International, Inc. (RV6) stocks in their portfolios, offering investors diversified exposure to the company. The ETFs are sorted by market value and provide details such as issuer, management style, expense ratio, AUM, price change, …

Charles River Labs stock trades around recent lows as investors weigh 2024 guidance and Discovery se

Charles River Laboratories stock is trading near its recent lows as investors evaluate the company's 2024 guidance and the sale of its Early Discovery business. The company, a key player in biopharmaceutical development, generated about $4.3 billion in revenue in 2023, with expectations for …

Charles River Laboratories International, Inc. Revenue Breakdown – NYSE:CRL

Charles River Laboratories International, Inc. (CRL) reported total revenue of $4.02 billion USD last year. The "Discovery and Safety Assessment" segment was the top performer, contributing $2.40 billion USD, although this was a slight decrease from the previous year. The United States remained the …

Charles River Laboratories International (CRL) Could Be 28% Undervalued On Its New Collaboration

Charles River Laboratories International (CRL) has announced a new collaboration with Arovella Therapeutics for GMP Next Generation Sequencing services, drawing significant attention. Despite this positive development and recent stock rebound, concerns remain regarding organic revenue and long-term performance. Various valuation models present conflicting views, …

CRL: Charles River Laboratories International Inc. Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock price, financial analysis, news, and trading ideas for Charles River Laboratories International Inc. (CRL). It includes current trading figures ($225.91, up 0.30%), market capitalization ($10.91B), and upcoming earnings date (Aug 5). The article also highlights recent news items …

Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors

Charles River Laboratories International Inc. (CRL) stock dropped 1.18% on Friday, closing at $226.58. This underperformance occurred despite a generally positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains. The company's stock also …

Charles River Laboratories stock hits 52-week high at $238.46

Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $238.46, reflecting strong investor confidence and a 34.75% increase over the past year. While analyst ratings are mixed, with some upgrading and others downgrading, the company's strategic collaborations and upcoming …

Charles River Laboratories International Inc (CRL) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 70/100

Charles River Laboratories International Inc (CRL) saw its stock rise by 4.8% to $229.29, but GuruFocus's GF Value indicates it is 18.2% overvalued with a fair value estimate of $193.98. The company has a GF Score of 70/100, suggesting above-average long-term returns, primarily due …

Charles River Laboratories International Inc. Stock Advances 4.8%, Outperforms Peers

Shares of Charles River Laboratories International Inc. advanced 4.8% to $229.29, despite a dismal trading session for the broader stock market, with the S&P 500 and Dow Jones Industrial Average both falling. This rise broke a four-day losing streak for the company, which closed …

CRL stock steadies as Charles River Laboratories focuses on growth after recent earnings

Charles River Laboratories (CRL) stock shows stability after its latest earnings report, with investors analyzing revenue trends, operating margins, and debt metrics. The company reported multi-billion dollar revenue in fiscal 2024, driven by demand in its Discovery and Safety Assessment segments, and provided an …

Charles River Laboratories Gains as Analysts Turn More Constructive Ahead of Earnings

Charles River Labs stock reflects mixed outlook as guidance reset follows scrutiny on Cambodian supp

Charles River Laboratories (CRL) stock is facing a complex outlook due to regulatory scrutiny over Cambodian suppliers and a reset in its 2024 guidance. Despite a slight revenue decline in 2023, the company anticipates a return to growth in 2024, driven by improved margin …

Charles River stock edges higher as guidance and drug development demand frame 2026 outlook

Charles River Laboratories (ISIN US1598641074) stock is seeing an uptick as investors evaluate its consistent demand for outsourced preclinical research, strong revenue growth, and expanding profit margins. The company's 2026 outlook is framed by robust drug development pipelines and the strategic importance of its …

CRL4900988 Bond Coupon Profile — Rate & Payments

This article provides details on the CRL4900988 bond, issued by Charles River Laboratories International, Inc. The bond has a current coupon rate of 4.25%, with the next payment scheduled for November 2, 2026. It offers an overview of the bond's interest payments and invites …

Price to sales forward of Charles River Laboratories International, Inc. – NYSE:CRL

This article provides the "Price to sales forward" metric for Charles River Laboratories International, Inc. (NYSE: CRL). The content primarily consists of navigation and branding elements from TradingView, which hosts financial data for the company. The core data point is presented simply as "Period …

Charles River Laboratories Earnings Preview: What to Expect

Charles River Laboratories (CRL) is set to release its fiscal Q2 2026 results on August 5th, with analysts expecting an adjusted EPS of $2.72, a 12.8% decrease year-over-year. Despite this, the company has consistently beaten Wall Street's bottom-line estimates and its stock has significantly …

Charles River Labs stock steadies as investors weigh recent earnings trends and outsourcing demand

Charles River Labs (CRL) stock is stable as investors evaluate the balance between strong demand for preclinical research outsourcing and recent margin pressures. The company has shown revenue growth driven by demand in discovery and safety assessment services, but profitability has been affected by …

CRL5145814 Bond Risk Profile

This page provides a risk profile for the CRL5145814 bond issued by Charles River Laboratories International, Inc., detailing its 3.75% coupon and March 15, 2029 redemption date. It offers an overview of credit risk assessment, including security level, inflation protection, and issuer rating, along …

CLSA downgrades Charles River Labs stock rating on valuation By Investing.com

CLSA downgraded Charles River Laboratories International Inc. (NYSE:CRL) from Outperform to Hold with a price target of $219.00, citing valuation concerns and the stock already reflecting a gradual recovery in early-stage R&D demand. Despite a recent boost from rotation into US healthcare, CLSA expects …

Charles River Labs stock steadies as revenue growth offsets regulatory headwinds

Charles River Laboratories stock (NYSE: CRL) has shown resilience, balancing steady revenue growth across its Discovery and Safety Assessment, Manufacturing Solutions, and Research Models and Services segments against recent regulatory challenges, particularly regarding non-human primate sourcing. The company's financial performance, characterized by multi-billion dollar …

Charles River Labs stock trades steady as recent revenue growth and margin trends frame investor foc

Charles River Labs stock is trading steadily, reflecting its revenue growth, but also navigating margin pressures from biologics services and significant investments in discovery and safety assessment. In fiscal 2023, the company reported revenues of approximately $4.1 billion, a 10-11% increase from 2022, primarily …

CRL4900987 Bond Risk Profile

This article provides a risk profile for the Charles River Laboratories International, Inc. 4.25% 01-MAY-2028 CRL4900987 bond, identified by FINRA. It highlights key metrics for credit risk assessment, including the bond's security level, inflation protection, and issuer rating. Additionally, it mentions the availability of …

Charles River Labs stock reflects recent earnings trends and regulatory overhang

Charles River Laboratories (NYSE: CRL) stock is influenced by slowing growth, regulatory scrutiny regarding its research models, and shifts in demand for outsourced preclinical services. The company recently reported quarterly revenue of approximately $1.0 billion, a mid-single-digit increase reflecting deceleration from previous periods, alongside …

CRL4900987 Bond Coupon Profile — Rate & Payments

This article provides a detailed coupon profile for the Charles River Laboratories International, Inc. 4.25% 01-MAY-2028 bond, identified by FINRA symbol CRL4900987. It highlights the current coupon rate of 4.25% and notes that the next interest payment is scheduled for November 2, 2026. The …

How Charles River’s Expanded GMP NGS Role in ALA-101 Testing Will Impact Charles River (CRL) Investors

Charles River Laboratories International (CRL) has expanded its GMP Next Generation Sequencing (NGS) capabilities through a collaboration with Arovella Therapeutics for ALA-101 testing and the acquisition of Pathoquest. This move reinforces Charles River's focus on high-value sequencing services for cell and gene therapies, though …

Charles River Labs stock trades steady as recent earnings and guidance frame valuation

Charles River Labs (NYSE: CRL) stock shows steady trading, reflecting a balance between its recent financial performance, updated guidance, and regulatory challenges. The company reported roughly $3.97 billion in total revenue and $10.50 non-GAAP diluted EPS for fiscal 2023, with segments like Manufacturing Solutions …

Pyrogen Testing Market Set for Strong Expansion | Charles River Laboratories International, Inc., Lonza Group AG

The global Pyrogen Testing Market is experiencing significant growth due to increased biopharmaceutical production, demand for sterile medical products, and strict regulatory requirements. Key drivers include the expansion of biologics and vaccines, regulatory mandates, and advancements in animal-free and automated testing methods. Challenges involve …

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will announce its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. Following the release, the company will host a conference call on the same day at 9:00 a.m. ET to discuss the results. …

Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day

Charles River Laboratories International Inc. (CRL) stock declined 1.29% to $228.22, despite an overall positive trading day for the stock market where the S&P 500 and Dow Jones Industrial Average rose. The company's stock closed 4.05% below its 52-week high of $237.86.

Charles River investors will get Q2 results before market open Aug. 5

Charles River Laboratories International, Inc. (NYSE: CRL) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. The company will also host a conference call at 9:00 a.m. ET on the same day to discuss these results. …